Skip to main content

Table 5 Medications in women with HFrEF and HFpEF subgroups

From: Clinical characteristics and in-hospital outcome of heart failure in women: a single center registry from Egyptian cardiac care unit

  HFrEF, n = 73 HFpEF, n = 45 P value
Thazides 5 (6.85%) 3 (6.7%) 0.969
Loop diuretics 40 (54.8%) 28 (62.22%) 0.428
Nitrates 39 (53.4%) 28 (62.22%) 0.349
Warfarin 17 (23.3%) 14 (31.11%) 0.348
Clopidogril 41 (56.2%) 17 (37.8%) 0.052
CCB 2 (2.74%) 6 (13.33%) 0.026
Amiodarone 10 (13.7%) 7 (15.6%) 0.780
Unfractunated heparin 19 (26.02%) 15 (33.33%) 0.395
LMWH 52 (71.23%) 27 (60%) 0.208
Lytic therapy 24 (32.88%) 8 (17.8%) 0.073
Aldosterone antagonist 32 (43.8%) 18 (40%) 0.682
Digixon 19 (26.03%) 13 (28.9%) 0.734
PPIH blockers 55 (75.34%) 42 (93.3%) 0.013
Warfarin A 10 (13.7%) 12 (26.7%) 0.079
ASA 60 (82.2%) 28 (62.22%) 0.016
Beta-blockers 27 (37%) 18 (40%) 0.743
ACEI 38 (52.1%) 22 (49%) 0.738
ARBs 8 (11%) 10 (22.22%) 0.098
Statin 58 (79.5%) 32 (71.1%) 0.301
  1. CCB calcium channel blockers, LMWH low molecular weight heparin, ASA acetyl salsylic acid, ACEI angiotensin converting enzyme inhibitor, ARBS angiotensin receptor blockers